1 of 1
Story summary
- Researchers at the University of Oklahoma identified the hormone FGF21, which may help reverse obesity by targeting a brain region that controls metabolism and appetite.
- The study, published in Cell Reports, suggests FGF21 could inform therapies for metabolic dysfunction-associated steatohepatitis (MASH).
- Hormone specialist Peter Balazs warned that results from mouse models may not translate to humans and noted potential side effects like digestive issues and bone loss.
- He highlighted that early human trials showed only modest weight loss compared to GLP-1 treatments, indicating the need for further safety trials before clinical use.
